UMB Bank, a trustee for Celgene’s former shareholders, has filed a lawsuit against Bristol Myers Squibb (BMS) for allegedly delaying the development and manufacturing of cancer drug lisocabtagene maraleucel (Liso-cel) to avoid contingent value right (CVR) payments worth $6.4bn.

Marketed as Breyanzi, Liso-cel is a treatment for the most common type of non-Hodgkin’s lymphoma. The drug was developed by Celgene, which BMS acquired in November 2019 for a total of approximately $74bn in cash and stock.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

As per the deal, Celgene shareholders would get a CVR of $9 for each share of the company’s stock as the milestone payment, which totals to $6.4bn, on US Food and Drug Administration (FDA) approval of three Celgene treatments.

The therapies include Breyanzi, a multiple sclerosis therapy, Ozanimod, and a multiple myeloma therapy, Ide-cel.

According to the complaint filed with Manhattan federal court, BMS breached the CVR agreement, which required the company to work on obtaining the FDA approval for Breyanzi by 31 December last year.

The FDA granted approval for Breyanzi on 5 February while BMS obtained approval for the two other drugs by the agreed deadlines.

By missing the deadline for Breyanzi, BMS was exempted from paying the milestone payment to Celgene shareholders, facilitating the company to make the acquisition at a ‘windfall market discount’, the complaint said.

UMB claimed that BMS withheld or belatedly submitted critical data to the FDA for Breyanzi’s approval and did not ready its manufacturing facilities for the regulator inspections.

UMB added: “Other cellular therapies based on similar technology have received FDA approval without the issues and ineptitude that plagued Bristol-Myers and in substantially less time.”

In a statement, BMS said: “We will not be commenting on pending litigation.”

In February, US Judge Dean Ochiai ordered BMS and Sanofi to pay over $834m to the state of Hawaii for illegally marketing their blood-thinning drug Plavix.